SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Makers Laboratories - Quaterly Results

22 May 2023 Evaluate
The revenue for the March 2023 quarter is pegged at Rs. 108.42 millions, about 20.09% up against Rs. 90.28 millions recorded during the year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -8.05 millions as compared to Net Loss of Rs. -16.03 millions of corresponding quarter ended March 2022 Operating profit Margin for the quarter ended March 2023 improved to 0.03% as compared to -9.45% of corresponding quarter ended March 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 108.42 90.28 20.09 425.47 523.76 -18.77 425.47 523.76 -18.77
Other Income 1.79 0.83 115.66 11.37 8.48 34.08 11.37 8.48 34.08
PBIDT 0.03 -9.45 -100.32 -29.97 38.97 -176.91 -29.97 38.97 -176.91
Interest 2.82 3.96 -28.79 13.81 16.75 -17.55 13.81 16.75 -17.55
PBDT -2.79 -13.41 -79.19 -43.78 22.22 -297.03 -43.78 22.22 -297.03
Depreciation 6.55 4.72 38.77 23.99 19.07 25.80 23.99 19.07 25.80
PBT -9.34 -18.13 -48.48 -67.77 3.15 -2251.43 -67.77 3.15 -2251.43
TAX -1.29 -2.10 -38.57 -4.15 1.41 -394.33 -4.15 1.41 -394.33
Deferred Tax -1.44 -1.58 -8.86 -4.30 1.08 -498.15 -4.30 1.08 -498.15
PAT -8.05 -16.03 -49.78 -63.62 1.74 -3756.32 -63.62 1.74 -3756.32
Equity 59.00 49.17 19.99 59.00 49.17 19.99 59.00 49.17 19.99
PBIDTM(%) 0.03 -10.47 -100.26 -7.04 7.44 -194.67 -7.04 7.44 -194.67

Makers Laboratories Share Price

155.80 -4.35 (-2.72%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×